Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.54 |
| ▸ | VNN1 | O95497 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17572995 | 0.87 | MCHR1 (0.54) | CCR5MCHR1PDK2NPY5RL3MBTL3 | |
| SCHEMBL95193 | 0.86 | MCHR1 (0.53) | CCR5MCHR1PDK2NPY5RL3MBTL3 | |
| SCHEMBL17559448 | 0.86 | MCHR1 (0.53) | CCR5MCHR1PDK2NPY5RL3MBTL3 | |
| Lithium Ion SCHEMBL17559446 | 0.84 | MCHR1 (0.52) | MCHR1PDK2NPY5RL3MBTL3 | |
| SCHEMBL17559476 | 0.83 | PDK2 (0.52) | CCR5MCHR1PDK2NPY5RL3MBTL3 | |
| SCHEMBL22624682 | 0.82 | PDK2 (0.54) | CCR5MCHR1PDK2VNN1 | |
| SCHEMBL28632797 | 0.82 | MEN1 (0.67) | PDK2 | |
| SCHEMBL3455662 | 0.80 | KCNH2 (0.63) | CCR5 | |
| SCHEMBL7407588 | 0.79 | CCR5 (0.52) | CCR5MCHR1PDK2VNN1CCR3 | |
| SCHEMBL7408110 | 0.78 | CCR5 (0.51) | CCR5MCHR1PDK2VNN1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1142910-C | Amide compound | ����ҩƷ��ҵ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040014745-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1235575-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| CN-1336917-A | Amide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-20 | — | — | CN | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140836-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000042011-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014745-A1 | Amide compounds | CHRM1, CHRM2, CHRNE | CCR5 2060/4885MCHR1 854/4885PDK2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.